Palmitoylethanolamide treatment for difficult-to-control ulcerative colitis
Part of Digestive system clinical trials.
This trial tests whether a natural compound called palmitoylethanolamide can help ulcerative colitis patients whose symptoms aren't controlled by standard medications. You'd be taking this alongside your current treatments to see if it reduces inflammation and symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of ulcerative colitis (an inflammatory bowel disease affecting the colon)
- Active mild-to-moderate disease that hasn't responded well to 5-ASA medications (standard first-line treatment) or requires steroid dependence
- Currently taking azathioprine (an immunosuppressant medication)
- No pregnancy, breastfeeding, active infections, uncontrolled diabetes or high blood pressure, or other autoimmune diseases
- No biologics (newer injectable medications), NSAIDs, or aspirin use
- No severe colitis requiring hospitalization, Crohn's disease, or other GI inflammatory conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding alpha lipoic acid (an antioxidant) to your usual mesalamine treatment helps control mild to moderate ulcerative colitis. It is for people newly diagnosed and not on other UC treatments.
This trial tests an oral medication called ponesimod for people with ulcerative colitis that hasn't responded well to other treatments. It aims to see if ponesimod can reduce inflammation and improve symptoms.
This study tests whether a new drug called Hemay005 can help people with moderate to severe ulcerative colitis (a chronic bowel condition causing inflammation and symptoms like diarrhea and abdominal pain) who haven't responded well to or can't tolerate standard treatments. The goal is to reduce inflammation and improve symptoms.
This study tests an experimental tablet for people with moderate to severe ulcerative colitis that hasn't improved with standard treatments. It aims to see if the tablet can reduce symptoms and inflammation.
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
This trial tests whether a natural substance called palmitoylethanolamide (PEA) can help reduce chronic low back pain by calming the nervous system and reducing inflammation. It might be an option for people with ongoing pain from a disc problem who haven't had surgery.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.